A majority had grade III breast cancer (n = 146, 69.5%) and either the HR+/HER2− (n = 88, 41.9%) or HR−/HER2− (triple-negative, n = 65, 31.0%) subtype, and 70 (33.3%) achieved pCR (Table 1). This evidence concerns the gene HR and breast cancer.